60 Degrees Pharmaceuticals, Inc. (SXTP): who owns it and who trades it
As of Nov 16, 2026, SXTP insiders reported 4 purchases worth $30.1K in the last 12 months. The largest buyer was Geoffrey S Dow (CEO), with $30.1K.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, SXTP insiders reported $30.1K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Geoffrey S Dow | CEO | Purchase | 7,350 | $1.38 | $10.1K | Form 4 |
| Dec 15, 2025 | Geoffrey S Dow | CEO | Purchase | 9,670 | $0.80 | $7.7K | Form 4 |
| Dec 11, 2025 | Geoffrey S Dow | CEO | Purchase | 3,613 | $0.92 | $3.3K | Form 4 |
| Dec 10, 2025 | Geoffrey S Dow | CEO | Purchase | 9,350 | $0.95 | $8.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Geoffrey S Dow | President and CEO, Director | $30.1K | – | Jun 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SXTP short interest
Moderate short interest. 7.3% of SXTP shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 80%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 255,088 SXTP shares were sold short, 7.3% of the shares outstanding, up 88.4% from the report before. At the average daily volume of 1.66M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 255,088 | 7.25% | +88% | 1.66M | 1.0 |
| Oct 15, 2026 | 135,408 | 3.85% | +2% | 336,684 | 1.0 |
| Sep 30, 2026 | 133,355 | 3.79% | -38% | 82,820 | 1.6 |
| Sep 15, 2026 | 215,989 | 6.14% | -16% | 72,803 | 3.0 |
| Aug 31, 2026 | 258,501 | 7.35% | -7% | 45,320 | 5.7 |
| Aug 14, 2026 | 277,184 | 7.88% | +35% | 79,344 | 3.5 |
| Jul 31, 2026 | 205,640 | 7.80% | +40% | 133,244 | 1.5 |
| Jul 15, 2026 | 146,408 | 5.55% | +30% | 95,701 | 1.5 |
| Jun 30, 2026 | 112,379 | 4.26% | -25% | 77,041 | 1.5 |
| Jun 15, 2026 | 150,674 | 5.71% | +16% | 165,490 | 1.0 |
| May 29, 2026 | 130,404 | 4.95% | -8% | 65,611 | 2.0 |
| May 15, 2026 | 141,535 | 5.37% | -1% | 57,831 | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
60 Degrees Pharmaceuticals company events
60 Degrees Pharmaceuticals filed 19 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.
- Nov 6, 2026Agreement60 Degrees Pharmaceuticals, Inc. entered into inducement offer letter agreements with certain holders of certain existing warrants to purchase up to an aggregate of 584,492 shares of the Company’s common stock, par value $0.0001 per share, originally issued on July 16, 2025, February 6, 2025… Filing
- Oct 27, 2026AnnouncementThe Company issued a press release announcing its clinical improvement and negative PCR results in all completed expanded access Babesiosis study patients. Filing
- Oct 23, 2026AnnouncementShared information with investors. Filing
- Oct 6, 2026AnnouncementThe Company issued a press release announcing an update to its January 2027 hospitalized babesiosis data readout. Filing
- Sep 14, 2026Announcement60 Degrees Pharmaceuticals, Inc. submitted a Statement of Interest to the U.S. Food and Drug Administration requesting a Commissioner’s National Priority Voucher designated for an efficacy supplement to NDA 210607 for ARAKODA ® (tafenoquine) for the treatment of babesiosis. Filing
- Sep 8, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026VoteReported shareholder vote results. Filing
- Aug 4, 2026Agreement60 Degrees Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell in a private placement offering an aggregate of (i) 191,571 shares of its common stock, par value $0.0001 per share at a… Filing
- Jul 20, 2026AnnouncementShared information with investors. Filing
- Jul 9, 2026AnnouncementThe Company prepared, and as of the date of this notice was preparing for submission to the U.S. Food and Drug Administration, a statistical analysis plan for the planned interim analysis of its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis… Filing
- Jun 3, 2026AnnouncementThe Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a… Filing
- May 18, 2026LeadershipThe Board of Directors of 60 Degrees Pharmaceuticals, Inc. appointed Eric Francois to serve as a member of the Board, effective immediately. Filing
- Mar 20, 2026AnnouncementThe Company determined that an error was made in the calculation of the number of shares of common stock beneficially owned by an affiliate of the Company, which was disclosed in the Company’s prospectus supplement dated March 13, 2026. Filing
- Mar 13, 2026Announcement60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel regarding the shares of common stock issued and sold under its “at-the-market” equity offering program pursuant to the Sales Agreement, dated September 5, 2025, entered into by and between the Company and HC Wainwright &… Filing
- Mar 12, 2026Announcement60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel regarding the shares of common stock issued and sold under its “at-the-market” equity offering program pursuant to the Sales Agreement, dated September 5, 2025, entered into by and between the Company and HC Wainwright &… Filing
- Feb 12, 2026AnnouncementAs previously disclosed, on January 20, 2026, 60 Degrees Pharmaceuticals, Inc. received a written notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq… Filing
- Jan 23, 2026Listing60 Degrees Pharmaceuticals, Inc. received a written notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. Filing
- Jan 21, 2026AnnouncementThe Company issued a press release with respect to the Reverse Stock Split described herein. Filing
- Jan 8, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
60 Degrees Pharmaceuticals financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named SXTP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 5.3% |
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 5.3% |
| Nov 12, 2026 | Orca Capital AG | 13G/A | 5.6% |
| Nov 12, 2026 | Orca Capital AG | 13G/A | 5.6% |
| Nov 10, 2026 | Mitchell P. Kopin | 13G/A | 10.0% |
| Nov 10, 2026 | Mitchell P. Kopin | 13G/A | 10.0% |
Questions about 60 Degrees Pharmaceuticals, Inc. (SXTP) stock
Are SXTP insiders buying or selling?
In the last 12 months, SXTP insiders reported 4 open-market purchases worth $30.1K and no sales. The latest trade was on Jun 12, 2026. See every trade.
What is the short interest in SXTP?
As of Oct 30, 2026, 255,088 SXTP shares were sold short, 7.3% of the shares outstanding, up 88.4% from the report before. At the average daily volume of 1.66M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.